Literature DB >> 28639536

Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.

Robert W Foley1, Nathan T Tagg2, Matthew K Schindler2, Kaylan M Fenton3, Daniel S Reich4, Irene Cortese2, Ellen M Mowry3.   

Abstract

Natalizumab is a recombinant humanized monoclonal antibody that decreases T-cell migration into the central nervous system (CNS) through α4 integrin:adhesion-molecule inhibition, thereby increasing the risk for opportunistic CNS infection. Herein, we report a case of infusion-associated aseptic meningitis in a patient receiving natalizumab.

Entities:  

Keywords:  MRI; Multiple sclerosis; disease-modifying therapies; natalizumab

Mesh：

Substances：

Year:  2017        PMID： 28639536      PMCID： PMC5562510          DOI： 10.1177/1352458517702533

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  14 in total

1.  Atypical multiple sclerosis presenting as chronic-progressive encephalomyelitis with polyneuritis and recurrent aseptic meningitis.

Authors:  C Börnke; H Przuntek; T Postert; K Schwechheimer; T Büttner
Journal:  J Neurol       Date:  1999-02       Impact factor: 4.849

2.  Case report of aseptic meningitis in a patient with Crohn's disease under infliximab therapy.

Authors:  Carolin Manthey; Ansgar W Lohse; Andrea Pace
Journal:  Inflamm Bowel Dis       Date:  2011-02       Impact factor: 5.325

3.  Aseptic meningitis possibly induced by adalimumab.

Authors:  Aurélie Jazeron; Jean-Charles Lallier; Boris Rihn; Marie-Catherine Thiercelin
Journal:  Joint Bone Spine       Date:  2010-07-24       Impact factor: 4.929

4.  Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.

Authors:  Reuben Mari Valenzuela; John H Pula; Dennis Garwacki; John Cotter; Jorge C Kattah
Journal:  J Neurol Sci       Date:  2014-03-11       Impact factor: 3.181

5.  Efalizumab-induced aseptic meningitis.

Authors:  N Kluger; C Girard; V Gonzalez; B Guillot; D Bessis
Journal:  Br J Dermatol       Date:  2007-01       Impact factor: 9.302

6.  High incidence of post-lumbar puncture headaches in patients with multiple sclerosis treated with natalizumab: role of intrathecal leukocytes.

Authors:  Olaf Stüve; Petra D Cravens; Mahendra P Singh; Elliot M Frohman; J Theodore Phillips; Gina Remington; Wei Hu; Bernhard Hemmer; Michael J Olek; Nancy L Monson; Michael K Racke
Journal:  Arch Neurol       Date:  2007-07

7.  Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients.

Authors:  Andrew J Fine; Alfred Sorbello; Cindy Kortepeter; Linda Scarazzini
Journal:  Clin Infect Dis       Date:  2013-05-31       Impact factor: 9.079

8.  Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center.

Authors:  Vighnesh Bharath; Kathleen Eckert; Matthew Kang; Ian H Chin-Yee; Cyrus C Hsia
Journal:  Transfusion       Date:  2015-06-20       Impact factor: 3.157

9.  The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis.

Authors:  Veronica Villani; Luca Prosperini; Laura De Giglio; Carlo Pozzilli; Marco Salvetti; Giuliano Sette
Journal:  Headache       Date:  2012-04-05       Impact factor: 5.887

10.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.